Presentation is loading. Please wait.

Presentation is loading. Please wait.

Best Practices in Management of HCV Genotypes 1, 4, 5, and 6 in 2014

Published byRuth Pearson Modified over 6 years ago

Similar presentations

Presentation on theme: "Best Practices in Management of HCV Genotypes 1, 4, 5, and 6 in 2014"— Presentation transcript:

1 Best Practices in Management of HCV Genotypes 1, 4, 5, and 6 in 2014
Michael W. Fried, MD Professor of Medicine Director, UNC Liver Center University of North Carolina at Chapel Hill Chapel Hill, North Carolina Supported by educational grants from multiple commercial supporters.

2 About These Slides Users are encouraged to use these slides in their own noncommercial presentations, but we ask that content and attribution not be changed. Users are asked to honor this intent These slides may not be published or posted online without permission from Clinical Care Options ( Disclaimer The materials published on the Clinical Care Options Web site reflect the views of the authors of the CCO material, not those of Clinical Care Options, LLC, the CME providers, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

3

4 Available HCV Therapies for Genotypes 1, 4, 5, and 6 and Key Data

5 Antiviral Therapies for Genotype 1 Currently Available
Regimen DAA Class PegIFN + RBV None PegIFN + RBV + boceprevir Protease inhibitor PegIFN + RBV + telaprevir PegIFN + RBV + simeprevir PegIFN+ RBV + sofosbuvir Nucleotide analogue NS5B polymerase inhibitor RBV + sofosbuvir* (Extended duration) Sofosbuvir + simeprevir NUC + PI (off-label) DAA, direct-acting antiviral; NUC, nucleotide analogue; PegIFN, peginterferon; PI, protease inhibitor; RBV, ribavirin. *Sofosbuvir + ribavirin for 24 wks can be considered in patients with genotype 1 HCV who are ineligible for interferon. AASLD/IDSA treatment recommendations. Available at: Accessed June 16, 2014.

6 Sofosbuvir + PegIFN/RBV: NEUTRINO Phase III Study Design
Wk 12 24 Sofosbuvir + PegIFN/RBV (N = 327) SVR12 Open label Sofosbuvir 400 mg QD + pegIFN alfa-2a 180 µg/wk + RBV mg/day for 12 wks (no response-guided therapy) Treatment-naive, genotype 1, 4, 5, and 6 HCV-infected patients 89% of patients had genotype 1 HCV 17% of patients with cirrhosis HCV, hepatitis C virus; PegIFN, peginterferon; QD, every day; RBV, ribavirin; SVR sustained virologic response. Lawitz E, et al. N Engl J Med. 2013;368:

7 NEUTRINO Study: Virologic Response
Sofosbuvir + PegIFN/RBV x 12 Wks 100 90 89 80 80 60 SVR (%) 40 GT1, genotype 1; ITT, intent to treat; PegIFN, peginterferon; RBV, ribavirin; SVR, sustained virologic response. 20 ITT SVR12 GT1 Cirrhosis n = 327 n = Lawitz E, et al. N Engl J Med. 2013;368:

8 Sofosbuvir + Low-Dose RBV
NIH SPARE Study (No Interferon): Sofosbuvir + RBV in HCV GT1–Infected Pts 24 wks sofosbuvir + WB or low-dose (600 mg) RBV in treatment-naive subjects Primarily GT1a (70%), male (66%), black (83%), IL28B CT/TT (81%) Advanced liver disease 23%; median BMI ranged from 26-30; high median HCV RNA Part 1 (Stage F0-F2) Part 2 (All Stages) 100 96 90 90 EOT SVR24 88 80 68 60 48 Patients (%) BMI, body mass index; EOT, end of treatment; GT, genotype; HCV, hepatitis C virus; ITT, intent to treat; NIH, National Institute of Health; RBV, ribavirin; SVR, sustained virologic response; WB, weight-based. 40 20 Sofosbuvir + WB RBV Sofosbuvir + Low-Dose RBV Sofosbuvir + WB RBV N = 10 N = 50 Osinusi A, et al. JAMA. 2013;310:

9 Response-Guided Treatment
Simeprevir + P/R in GT1, Tx-Naive Patients: QUEST-1/2 Phase III Trial Design Response-Guided Treatment SMV 150 mg QD + P/R P/R P/R N = 521* Placebo + P/R P/R P/R N = 264† Wk 12 24 48 72 RGT in simeprevir arm: if HCV RNA < 25 IU/mL at Wk 4 and undetectable at Wk 12, complete treatment at Wk 24; otherwise, continue treatment to Wk 48 Stopping rules If HCV RNA > 1000 IU/mL Wk 4, stop SMV/placebo If HCV RNA < 2 log10 IU/mL reduction at Wk 12, or confirmed > 25 IU/mL at Wk 24 or 36, stop all treatment GT, genotype; P/R, peginterferon alfa-2a 180 µg/wk + ribavirin mg/day; QD, every day; RGT, response-guided treatment; SMV, simeprevir; Tx, treatment. *QUEST-1: n = 264; QUEST-2: n = 257. †QUEST-1: n = 130; QUEST-2: n = 134. Jacobson I, et al. EASL Abstract Manns M, et al. EASL Abstract 1413.

10 Simeprevir + P/R: Phase III QUEST-1: Impact of Subtype & Fibrosis Stage in GT1
Overall GT1a GT1b F0-F F F4 100 90 100 83 80 78 80 71 80 58 60 60 52 60 50 49 SVR (%) 40 40 26 29 20 20 GT, genotype; P/R, peginterferon/ribavirin; SVR, sustained virologic response. Simeprevir P/R Simeprevir P/R SVR: GT1b > GT1a SVR is lowest for patients with GT1a and baseline Q80K mutation SVR: F0-F2 > F4 Jacobson I, et al. EASL Abstract 1425.

11 Multiple Classes of Direct-Acting Antiviral Agents
5’UTR Core E1 E2 NS2 NS3 NS4B NS5A NS5B 3’UTR p7 Protease Polymerase Ribavirin NS3 Protease Inhibitors NS5A Replication Complex Inhibitors NS5B NUC Inhibitors NS5B Non-NUC Inhibitors Telaprevir Boceprevir Simeprevir Asunaprevir ABT-450 MK-5172 Faldaprevir Sovaprevir ACH-2684 Daclatasvir Ledipasvir Ombitasvir MK-8742 GS-5885 GS-5816 ACH-3102 PPI-668 GSK Samatasvir Sofosbuvir VX-135 IDX21437 ACH-3422 Dasabuvir BMS PPI-383 GS-9669 TMC647055 NUC, nucleotide analogue. *Representative list; may not be fully inclusive.

12 COSMOS: Simeprevir + Sofosbuvir ± RBV in GT1 HCV: Phase IIa Study Design
4 12 24 36 48 Wk Arm 1 SMV + SOF + RBV Posttreatment follow-up Arm 2 SMV + SOF Posttreatment follow-up Enrolment ratio 2:1:2:1 Arm 3 SMV + SOF + RBV Posttreatment follow-up Arm 4 SMV + SOF Posttreatment follow-up GT, genotype; HCV, hepatitis C virus; QD, every day; RBV, ribavirin; SMV, simeprevir; SOF, sofosbuvir. Cohort 1: previous null responders (METAVIR F0-F2) Cohort 2: treatment naive and previous null responders (METAVIR F3-F4) SMV 150 mg QD + SOF 400 mg QD ± RBV 1000/1200 mg/day Jacobson I, et al. AASLD Abstract LB-3. Lawitz, et al. EASL Abstract 165.

13 Combination of Sofosbuvir (NUC) and Simeprevir (PI): COSMOS
Cohort 1 (F0-F2 Nulls): SVR12 (N = 80, all arms) Cohort 2 (F3-F4 Naives/Nulls): SVR12 (N = 87, all arms) SMV + SOF + RBV SMV + SOF 100 100 96.3 100 93.3 92.9 93 93 93 79.2 80 80 60 60 SVR12 (%) SVR12 (%) 40 40 20 20 AE, adverse effects; GT, genotype; NUC, nucleotide analogue; PI, protease inhibitor; RBV, ribavirin; SMV, simeprevir; SOF, sofosbuvir; SVR, sustained virologic response. 19/24 14/15 26/27 13/14 28/30 16/16 25/27 13/14 24-Wk Arms 12-Wk Arms 24-Wk Arms 12-Wk Arms Relapse in 3 pts in cohort 1 and 3 pts in cohort 2; all with GT1a and GT2 with Q80K polymorphism at baseline AEs (anemia and indirect bilirubin increases) largely confined to RBV arms SVR in patients with GT1a and Q80K+ = 88% to 100% Jacobson I, et al. AASLD Abstract LB-3. Lawitz E, et al. EASL Abstract 165.

14 How to Use Current Therapies in Genotypes 1, 4, 5, and 6

15 AASLD/IDSA Recommendations for HCV Genotype 1 Treatment-Naive Patients
Yes IFN Eligible? No Sofosbuvir 400 mg/d PEG + RBV x 12 wks Sofosbuvir 400 mg/d Simeprevir 150 mg/d ± RBV x 12 wks Alternative Regimens AASLD/IDSA, American Association for the Study of Liver Diseases/Infectious Diseases Society of America; HCV, hepatitis C virus; IFN, interferon; PEG, peginterferon; RBV, ribavirin. Simeprevir 150 mg/d x 12 wks + PEG + RBV x 24 wks GT1b GT1a Q80K neg Sofosbuvir 400 mg/d + RBV x 24 wks RBV dose: mg/day AASLD/IDSA treatment recommendations.

16 AASLD/IDSA Recommendations for HCV Genotype 1 Treatment-Experienced Pts
Yes/No Prior Protease Inhibitor? No Sofosbuvir 400 mg/d x 12 wks + PEG + RBV x wks Sofosbuvir 400 mg/d Simeprevir 150 mg/d ± RBV x 12 wks Alternative Regimens AASLD/IDSA, American Association for the Study of Liver Diseases/Infectious Diseases Society of America; HCV, hepatitis C virus; PEG, peginterferon; RBV, ribavirin. Sofosbuvir 400 mg/d + RBV ± PEG x 24 wks Sofosbuvir 400 mg/d x 12 wks + PEG + RBV x 12 wks Simeprevir 150 mg/d x 12 wks + PEG + RBV x 48 wks GT1b GT1a Q80K neg RBV dose: mg/day AASLD/IDSA treatment recommendations.

17 Sofosbuvir + PegIFN/RBV: Phase III NEUTRINO Study (GT1, 4, 5, 6)
Sofosbuvir + PegIFN/RBV x 12 Wks 97 100 90 80 80 60 SVR (%) 40 GT, genotype; ITT, intent to treat; pegIFN, peginterferon; RBV, ribavirin; SVR, sustained virologic response. 20 ITT SVR12 GT4, 5, 6 Cirrhosis n = 327 n = n = 54 Lawitz E, et al. N Engl J Med. 2013;368:

18 AASLD/IDSA Recommendations for HCV Genotype 4 Treatment-Naive Patients
Yes IFN Eligible? No Sofosbuvir 400 mg/d + PEG + RBV x 12 wks Sofosbuvir 400 mg/d + RBV x 24 wks AASLD/IDSA, American Association for the Study of Liver Diseases/Infectious Diseases Society of America; HCV, hepatitis C virus; IFN, interferon; PEG, peginterferon; RBV, ribavirin. Alternative Regimens Simeprevir 150 mg/d + PEG + RBV x wks RBV dose: mg/day AASLD/IDSA treatment recommendations.

19 Treatment Experienced
AASLD/IDSA Recommendations for HCV Genotype 4 Treatment-Experienced Pts Genotype 4 Treatment Experienced Sofosbuvir 400 mg/d + PEG + RBV x 12 wks AASLD/IDSA, American Association for the Study of Liver Diseases/Infectious Diseases Society of America; HCV, hepatitis C virus; PEG, peginterferon; RBV, ribavirin. Alternative Regimens Sofosbuvir 400 mg/d + RBV x 24 wks RBV dose: mg/day AASLD/IDSA treatment recommendations.

20 Adverse Effects of New Therapies
PegIFN/RBV: well-established AE profiles Sofosbuvir[1-3] Mild fatigue Mild headache Simeprevir[4,5] Mild, reversible hyperbilirubinemia Due to transporter inhibition and not associated with hepatotoxicity Mild photosensitivity AE, adverse effect; PegIFN/RBV, peginterferon/ribavirin. 1. Lawitz E, et al. N Engl J Med. 2013;368: Jacobson I, et al. AASLD Abstract LB Sofosbuvir [package insert]. 4. Fried MW, et al. Hepatology. 2013;58: Simeprevir [package insert].

21 Considerations for Monitoring During Therapy
Medications are costly: focus on pretreatment education to maximize adherence PegIFN/RBV + DAA regimens Addition of DAA generally does not augment AE profile Continue to monitor every 2 wks x 4, then monthly (cytopenias, depression, etc) DAA + RBV only regimens Anemia still occurs, monitor every 2 wks x 4, then monthly DAA + DAA regimens Individualized follow-up Wk 2 and Wk 4, then every 4 wks? Adherence is key to success AE, adverse effect; DAA, direct-acting antiviral; PegIFN/RBV, peginterferon/ribavirin.

22 Summary: How Do We Treat Patients Now?
Multiple therapeutic options are available for patients with genotypes 1 and 4 with: Shorter durations of treatment Increased efficacy Fewer adverse effects Genotype 1, 4, 5, 6 DAA + pegIFN/RBV backbone still may be used in selected patients All oral regimens also available as on-label and off-label recommendations DAA, direct-acting antiviral; pegIFN/RBV, peginterferon/ribavirin.

23 What’s Coming Next? Investigational Therapies for Genotypes 1, 4, 5, and 6

24 ION-2[3] Treatment-experienced HCV GT1; 20% cirrhotics (N = 440)
Phase III Studies of SOF/LDV FDC ± RBV for 12 or 24 Wks in GT1 Patients Wk 12 Wk 24 SVR12, % 99 97 98 SOF/LDV (n = 214) ION-1[1,2] Treatment-naive HCV GT1; cirrhosis in 15% to 17% per arm (N = 865) SOF/LDV + RBV (n = 217) SOF/LDV (n = 217) SOF/LDV + RBV (n = 217) Wk 12 Wk 24 94 96 99 SOF/LDV (n = 109) ION-2[3] Treatment-experienced HCV GT1; 20% cirrhotics (N = 440) GT, genotype; FDC, fixed-dose combination; HCV, hepatitis C virus; RBV, ribavirin; SOF/LDV, sofosbuvir/ledipasvir; SVR, sustained virologic response. SOF/LDV + RBV (n = 111) SOF/LDV (n = 109) SOF/LDV + RBV (n = 111) ION-1,2: No difference in outcomes according to cirrhosis status, type of treatment failure 1. Mangia A, et al. EASL Abstract O Afdhal N, et al. N Engl J Med. 2014;370: Afdhal N, et al. N Engl J Med. 2014;370:

25 Treatment-naive, noncirrhotic pts with HCV GT1 (N = 647)
ION-3: Phase III Study of SOF/LDV FDC ± RBV for 8-12 Wks in Tx-Naive Noncirrhotic GT1 Patients Wk 8 Wk 12 SVR12, % SOF/LDV (n = 215) 94 93 95 Treatment-naive, noncirrhotic pts with HCV GT1 (N = 647) SOF/LDV + RBV (n = 216) SOF/LDV (n = 216) GT, genotype; FDC, fixed-dose combination; HCV, hepatitis C virus; RBV, ribavirin; SOF/LDV, sofosbuvir/ledipasvir; SVR, sustained virologic response; Tx, treatment. Kowdley KV, et al. N Engl J Med. 2014;

26 Treatment-naive noncirrhotic pts with HCV GT1[1,2] (N = 631)
SAPPHIRE I & II: Phase III Studies of ABT-450/RTV/Ombitasvir (NS5A) + Dasabuvir (NNI) + RBV in Noncirrhotic GT1 Pts Wk 12 SVR12, % SAPPHIRE-I Treatment-naive noncirrhotic pts with HCV GT1[1,2] (N = 631) ABT450/RTV/Ombitasvir + Dasabuvir + RBV (n = 473) 96 Placebo (n = 158)* SAPPHIRE-II Treatment-experienced noncirrhotic pts with HCV GT1[3,4] (N = 394) ABT450/RTV/Ombitasvir + Dasabuvir + RBV (n = 297) Placebo (n = 97) GT, genotype; HCV, hepatitis C virus; NNI, nonnucleoside inhibitor; RBV, ribavirin; RTV, ritonavir; SVR, sustained virologic response. SAPPHIRE: no difference in outcomes according to 1a/1b subtype, type of treatment failure *Placebo recipients crossed over to active treatment regimen at Wk 12. 1. Feld JJ, et al. EASL Abstract O60. Reproduced with permission. 2. Feld JJ, et al. N Engl J Med. 2014;370: Zeuzem S, et al. EASL Abstract O1. 4. Zeuzem S, et al. N Engl J Med. 2014;370:

27 TURQUOISE II: Phase III Study of ABT-450/RTV/Ombitasvir (NS5A) + Dasabuvir (NNI) + RBV in Cirrhotic GT1 Patients Wk 12 Wk 24 SVR12, % ABT450/RTV/Ombitasvir + Dasabuvir + RBV (n = 208) DAA-naive cirrhotic pts with HCV GT1; 58% of patients were treatment experienced, and 36% were previous null responders (N = 380) 92 96 ABT450/RTV/Ombitasvir + Dasabuvir + RBV (n = 172) DAA, direct-acting antiviral; GT, genotype; HCV, hepatitis C virus; NNI, non-nucleoside inhibitor; RBV, ribavirin; RTV, ritonavir; SVR, sustained virologic response. No significant difference in 12 vs 24 wks; high SVR in all subgroups analyzed ABT-450/RTV/ombitasvir 150/100/25 mg once daily; dasabuvir 250 mg twice daily; RBV mg/day. Poordad F, et al. N Engl J Med. 2014;370:

28 Ribavirin-Free Therapy in GT1b
Wk 12 SVR12, % PEARL-II[1] ABT450/RTV/Ombitasvir + Dasabuvir (n = 95) 100 GT1b Tx Experienced ABT450/RTV/Ombitasvir + Dasabuvir + RBV (n = 91) 97 PEARL-III[2] ABT450/RTV/Ombitasvir + Dasabuvir (n = 209) 99 GT1b Tx Naive ABT450/RTV/Ombitasvir + Dasabuvir + RBV (n = 210) 99 GT, genotype; RBV, ribavirin; RTV, ritonavir; SVR, sustained virologic response; Tx, treatment. PEARL-IV[2] ABT450/RTV/Ombitasvir + Dasabuvir (n = 205) 90 GT1a Tx Naive ABT450/RTV/Ombitasvir + Dasabuvir + RBV (n = 100) 97 1. Andreone P, et al. Gastroenterology. 2014;[Epub ahead of print]. 2. Ferenci P, et al. N Engl J Med ;370:

29 C-WORTHY: MK-5172 + MK-8742 ± RBV in GT1 Patients With Cirrhosis and in Null Responders
Wk 12 Wk 18 SVR4/8, % MK MK RBV (n = 31) 90 97 94 91 100 Treatment-naive patients with GT1 HCV and cirrhosis (N = 123) MK MK-8742 (n = 29) MK MK RBV (n = 32) MK MK-8742 (n = 31) MK MK RBV (n = 31) GT, genotype; HCV, hepatitis C virus; pegIFN, peginterferon; RBV, ribavirin; SVR, sustained virologic response. Patients with GT1 HCV and null response to pegIFN/RBV (N = 130) MK MK-8742 (n = 33) MK MK RBV (n = 33) MK MK-8742 (n = 32) MK mg once daily; MK mg once daily, RBV mg divided twice daily. Lawitz E, et al. EASL Abstract O61.

30 AI : Phase IIb Study of Daclatasvir + Asunaprevir + BMS in Noncirrhotic GT1 HCV Patients Stratified by GT1 subtype and biopsy-confirmed cirrhosis Wk 12 SVR12,* % Daclatasvir + Asunaprevir + BMS mg BID (n = 80) 89 90 Tx-naive pts with GT1 HCV (N = 166) Daclatasvir + Asunaprevir + BMS mg BID (n = 86) BID, twice daily; GT, genotype; HCV, hepatitis C virus; ITT, intent to treat; P/R/ peginterferon/ribavirin; SVR, sustained virologic response; Tx, treatment. Daclatasvir 30 mg BID; asunaprevir 200 mg BID *Modified ITT analysis: missing data, breakthrough, relapse, or addition of P/R equals failure. Everson GT, et al. AASLD Abstract LB-1.

31 Summary Multiple all-oral DAA regimens will be available over the next mos: Dual and triple DAA regimens yield the highest SVR rates (90%+) ever described Treatment duration of 12 wks (maybe shorter) Well tolerated across all populations Importance of RBV varies with regimen and virologic characteristics Preliminary data indicate that traditionally difficult to cure populations (cirrhosis, previous PI failures) will benefit greatly from IFN/RBV-free DAA regimens DAA, direct-acting antiviral; IFN, interferon; PI, protease inhibitor; RBV, ribavirin; SVR, sustained virologic response.

Download ppt "Best Practices in Management of HCV Genotypes 1, 4, 5, and 6 in 2014"

Similar presentations

Future Trials of Hepatitis C Therapy in the HIV Co-infected Stephen D. Shafran, MD, FRCPC, FACP Department of Medicine, Division of Infectious Diseases.

Future Trials of Hepatitis C Therapy in the HIV Co-infected Stephen D. Shafran, MD, FRCPC, FACP Department of Medicine, Division of Infectious Diseases.
Future Directions in HCV Therapy Eric Lawitz, MD, AGAF,CPI Medical Director, The Texas Liver Institute Clinical Professor of Medicine University of Texas.

Future Directions in HCV Therapy Eric Lawitz, MD, AGAF,CPI Medical Director, The Texas Liver Institute Clinical Professor of Medicine University of Texas.
Recent HCV treatment developments: In pursuit of perfectovir Professor Greg Dore Kirby Institute, UNSW Australia; & St Vincent’s Hospital, Sydney.

Recent HCV treatment developments: In pursuit of perfectovir Professor Greg Dore Kirby Institute, UNSW Australia; & St Vincent’s Hospital, Sydney.
Slide 1 of 8 From DL Wyles, MD, at Atlanta, GA: April 10, 2013, IAS-USA. IAS–USA David L. Wyles, MD Associate Professor of Medicine University of California.

Slide 1 of 8 From DL Wyles, MD, at Atlanta, GA: April 10, 2013, IAS-USA. IAS–USA David L. Wyles, MD Associate Professor of Medicine University of California.
Hepatitis web study Hepatitis web study Sofosbuvir in HCV Genotype 2, 3 (PEG not an Option) POSITRON Phase 3 *Note: Published in tandem with FUSION Trial.

Hepatitis web study Hepatitis web study Sofosbuvir in HCV Genotype 2, 3 (PEG not an Option) POSITRON Phase 3 *Note: Published in tandem with FUSION Trial.
The new Treatments Dr John F Dillon. Curing one person Curing a population one person at a time.

The new Treatments Dr John F Dillon. Curing one person Curing a population one person at a time.
HCV 2014 and beyond the interferon era Patrick M. Horne, MSN, ARNP, FNP-BC Assistant Director of Hepatology Clinical Research Division of Gastroenterology,

HCV 2014 and beyond the interferon era Patrick M. Horne, MSN, ARNP, FNP-BC Assistant Director of Hepatology Clinical Research Division of Gastroenterology,
Hepatitis web study H EPATITIS W EB S TUDY H EPATITIS C O NLINE Treatment of Chronic HCV Genotype 1 Robert G. Gish MD Staff Physician, Stanford University.

Hepatitis web study H EPATITIS W EB S TUDY H EPATITIS C O NLINE Treatment of Chronic HCV Genotype 1 Robert G. Gish MD Staff Physician, Stanford University.
Hepatitis web study Hepatitis web study Sofosbuvir + Peginterferon + Ribavirin in Genotype 2 or 3 LONESTAR-2 Phase 2 Treatment Experienced Lawitz E, et.

Hepatitis web study Hepatitis web study Sofosbuvir + Peginterferon + Ribavirin in Genotype 2 or 3 LONESTAR-2 Phase 2 Treatment Experienced Lawitz E, et.
Hepatitis web study Hepatitis web study Hepatitis web study Hepatitis web study Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir + RBV in GT1 SAPPHIRE-II.

Hepatitis web study Hepatitis web study Hepatitis web study Hepatitis web study Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir + RBV in GT1 SAPPHIRE-II.
Hepatitis web study Hepatitis web study Hepatitis web study Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir + RBV in GT1 TURQUOISE-II Phase 3 Treatment.

Hepatitis web study Hepatitis web study Hepatitis web study Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir + RBV in GT1 TURQUOISE-II Phase 3 Treatment.
Hepatitis web study Hepatitis web study Hepatitis web study Hepatitis web study Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir + RBV in GT1 SAPPHIRE-I.

Hepatitis web study Hepatitis web study Hepatitis web study Hepatitis web study Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir + RBV in GT1 SAPPHIRE-I.
Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2 Phase 3 Treatment Experienced Source: Afdhal N, et.

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2 Phase 3 Treatment Experienced Source: Afdhal N, et.
Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir for 8 or 12 weeks in HCV GT1 ION-3 Phase 3 Treatment Naïve Kowdley K, et al. N Engl J Med.

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir for 8 or 12 weeks in HCV GT1 ION-3 Phase 3 Treatment Naïve Kowdley K, et al. N Engl J Med.
Hepatitis web study Hepatitis web study Simeprevir + Sofosbuvir +/- Ribavirin in Genotype 1 COSMOS Trial Phase 2a, Treatment Naïve and Treatment Experienced.

Hepatitis web study Hepatitis web study Simeprevir + Sofosbuvir +/- Ribavirin in Genotype 1 COSMOS Trial Phase 2a, Treatment Naïve and Treatment Experienced.
Hepatitis web study Hepatitis web study Simeprevir + PEG + RBV in Treatment-Naïve Genotype 1 QUEST-2 Trial Phase 3 Treatment Naïve Manns M, et al. Lancet.

Hepatitis web study Hepatitis web study Simeprevir + PEG + RBV in Treatment-Naïve Genotype 1 QUEST-2 Trial Phase 3 Treatment Naïve Manns M, et al. Lancet.
Hepatitis web study Hepatitis web study Simeprevir + PEG + RBV in Treatment-Naïve Genotype 1 QUEST-1 Trial Phase 3 Treatment Naïve Jacobson IM, et al.

Hepatitis web study Hepatitis web study Simeprevir + PEG + RBV in Treatment-Naïve Genotype 1 QUEST-1 Trial Phase 3 Treatment Naïve Jacobson IM, et al.
Hepatitis web study H EPATITIS W EB S TUDY H EPATITIS C O NLINE Simeprevir (Olysio) Prepared by: David Spach, MD & H. Nina Kim, MD Last Updated: October.

Hepatitis web study H EPATITIS W EB S TUDY H EPATITIS C O NLINE Simeprevir (Olysio) Prepared by: David Spach, MD & H. Nina Kim, MD Last Updated: October.
Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir in Treatment-Experienced GT1 with Cirrhosis SIRIUS Phase 2 Treatment Experienced Bourliere.

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir in Treatment-Experienced GT1 with Cirrhosis SIRIUS Phase 2 Treatment Experienced Bourliere.
Hepatitis web study Hepatitis web study 3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) +/- RBV in GT1b PEARL-II Phase 3 Treatment Experienced Andreone.

Hepatitis web study Hepatitis web study 3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) +/- RBV in GT1b PEARL-II Phase 3 Treatment Experienced Andreone.

Similar presentations

Ads by Google